Business Context and Reporting Period
This Form 8-K Current Report was filed by Protara Therapeutics, Inc. on December 7, 2020, covering events occurring on December 1, 2020. The filing addresses corporate governance changes, specifically the promotion of an executive officer and associated compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation matters rather than financial performance.
Material Changes
The primary material change reported is the promotion of Jacqueline Zummo, Ph.D., MPH, MBA, from Senior Vice President, Research Operations, to Chief Scientific Operations Officer, effective January 1, 2021. This change includes:
- Base Salary: Increased to $405,000 annually.
- Performance Bonus: Increased to 40% of the then-current base salary.
- Equity Grant: Approval of a stock option to purchase 66,700 shares of common stock, to be granted on January 4, 2021.
Outlook, Risks, and Unusual Items
The stock option grant is subject to the Company's Amended and Restated 2014 Equity Incentive Plan. The exercise price will be determined by the closing price of the Common Stock on The Nasdaq Capital Market on the grant date. Vesting is scheduled over four years of continuous service, with 25% vesting after one year and the remainder vesting monthly thereafter. No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the closing stock price on January 4, 2021, to determine the exercise price of the 66,700 options granted to Dr. Zummo.
- Confirm the effective date of the new compensation package (January 1, 2021) against payroll records.
- Review the Company's 2014 Equity Incentive Plan to ensure the grant complies with available share reserves.
- Monitor future filings for any additional executive departures or appointments.